|
Report Date : |
07.08.2012 |
IDENTIFICATION DETAILS
|
Name : |
DAEWOONG BIO INC. |
|
|
|
|
Registered Office : |
906-5, Sangsin-ri, Hyangnam-eup,
Hwaseong-si, Gyeonggi-do, Korea, Hyangnam
Pharmaceutical Industries Complex, Zip Code 445-922 |
|
|
|
|
Country : |
South korea |
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Date of Incorporation : |
02.04.2009 |
|
|
|
|
Com. Reg. No.: |
124-86-77584 |
|
|
|
|
Legal Form : |
Co., Ltd by shares |
|
|
|
|
Line of Business : |
Manufacture of Medicinal Chemicals and Antibiotics |
|
|
|
|
No. of Employees : |
158 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
|
Company
Name |
DAEWOONG BIO INC. (Korean Company Name : “대웅바이오(주)”) |
|
Registered Address |
906-5, Sangsin-ri, Hyangnam-eup,
Hwaseong-si, Gyeonggi-do, Korea |
|
Building |
Hyangnam Pharmaceutical Industries Complex |
|
Zip Code |
445-922 |
|
Tel |
+82-31-353-5271~3 |
|
Fax |
+82-31-353-5626 |
|
E-mail |
|
|
Website |
|
|
Trading Address |
Daewoong Pharmaceutical Bldg.,163-3, Samseong-dong,
Gangnam-gu, Seoul, Korea |
|
Tel |
+82-2-550-8641 |
|
Fax |
+82-2-550-8249 |
|
Type |
Export/Import |
|
Industry |
Manufacture of Medicinal Chemicals and Antibiotics |
|
Main Business |
Ursodeoxycholic Acid, Amoxicillin, Ceftriaxone Sodium, Coenzyme Q10,
Cefodizime Sodium, Cefotiam Hydrochloride, Lansoprazole, Fluconazole |
|
Established (mm/dd/yyyy) |
04/02/2009 |
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Drugs and Pharmaceutical Products(51000000) |
|
Sell |
Penicillin(51101507) |
|
Name |
Lee Jong-Wook |
|
Address |
Suite 117-603, 155, Seongbok-dong,
Suji-gu, Yongin-si, Gyeonggi-do, Korea |
|
Date of Birth |
03/10/1949 |
|
Title |
Co-President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital (KRW) |
1,000,000,000 |
|||||||||
|
Employees |
158 |
|||||||||
|
Formation |
Co., Ltd by shares A Company of DAEWOONG GROUP |
|||||||||
|
Bank Details |
Woori Bank-Samsung Dong Branch Shanhan Bank |
|||||||||
|
Corporate Registered No. |
134811-0172221 |
|||||||||
|
Business Registered No. |
124-86-77584 |
|||||||||
|
Permit & Licenses |
Int’l Trade No.: 45370498 |
|||||||||
|
Shareholder Position |
|
|||||||||
|
Company History |
04/02/2009
Incorporated as the present name after spinning off Raw Materials Business
for Pharmaceuticals from DAEWOONG CHEMICAL CO., LTD.(131112-0004827) located at 906-5, Sangsin-ri, Hyangnam-eup,
Hwaseong-si, Gyeonggi-do, Korea. 06/28/2010 Changed the financial closing
date to December 31 from March 31 |
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
Co-President & CEO |
Mr. |
Lee Jong-Wook |
Male |
Korean |
12/10/2009 |
|
Co-President & CEO |
Mr. |
Yoon Jae-Seung |
Male |
Korean |
06/08/2009 |
|
Director |
Mr. |
Yoon Jae-Hoon |
Male |
Korean |
04/02/2009 |
|
Director |
Mr. |
Yoon Jae--Choon |
Male |
Korean |
04/02/2009 |
|
Director |
Mr. |
Seo Jong-Won |
Male |
Korean |
06/28/2010 |
|
Auditor |
Mr. |
Lee Won-Keun |
Male |
Korean |
03/30/2012 |
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
132,837,744,799 |
176,380,999,684 |
8,850,003,832 |
|
|
12/2010 |
91,698,215,718 |
135,023,006,082 |
7,507,357,320 |
|
03/2010 |
101,131,109,420 |
96,739,291,272 |
9,026,412,992 |
|
03/2009 |
|
|
|
|
Authorized Capital(KRW) |
5,000,000,000 |
|
Paid-Up Capital(KRW) |
1,000,000,000 |
|
Total Issues Shares |
200,000 |
Balance
Sheet
|
|||
|
Unit : Korean Won |
As of 12/31/2011 |
As of 12/31/2010 |
As of 12/31/2009 |
|
Total
Assets |
176,380,999,684 |
135,023,006,082 |
|
|
Current Assets |
73,521,775,239 |
47,860,274,957 |
|
|
Cash
& Cash Equivalents |
3,981,176,387 |
1,191,566,962 |
|
|
Trade
Receivables & Other Receivables |
37,529,361,334 |
25,523,337,878 |
|
|
Inventories |
26,289,328,877 |
16,002,023,830 |
|
|
Other Current Assets |
5,721,908,641 |
5,143,346,287 |
|
|
Non-Current Assets |
102,859,224,445 |
87,162,731,125 |
|
|
Marketable
Financial Instruments |
119,945,000 |
546,555,000 |
|
|
Long-Term
Trade Receivables & Other Receivables |
472,896,062 |
87,927,062 |
|
|
Investment_Subsidiaries |
4,026,762,100 |
3,349,614,050 |
|
|
Investment_Related
Companies |
1,271,142,157 |
1,271,142,157 |
|
|
Tangibles |
87,178,321,231 |
72,338,965,267 |
|
|
Investment_Real
Estates |
6,612,478,819 |
6,667,796,246 |
|
|
Intangibles |
2,600,448,072 |
2,653,077,232 |
|
|
Deferred Income Tax Assets |
577,231,004 |
247,654,111 |
|
|
Total
Liabilities |
87,086,267,064 |
54,720,916,387 |
|
|
Current Liabilities |
74,315,425,967 |
38,992,544,582 |
|
|
Trade
Payables & Other Payables |
35,057,398,224 |
26,431,590,430 |
|
|
Short-Term Borrowings |
29,498,365,511 |
10,365,183,746 |
|
|
Current Portion of Long-Term Borrowings |
9,000,000,000 |
- |
|
|
Deferred Income Tax Assets |
156,595,182 |
1,670,652,506 |
|
|
Other Current Liabilities |
603,067,050 |
525,117,900 |
|
|
Non-Current Liabilities |
12,770,841,097 |
15,728,371,805 |
|
|
Long-Term Trade Payables & Other Payables |
3,000,000,000 |
3,000,000,000 |
|
|
Long-Term Borrowings |
9,000,000,000 |
12,000,000,000 |
|
|
Provision for Severance &
Retirement |
770,841,097 |
728,371,805 |
|
|
Capital Stock |
1,000,000,000 |
1,000,000,000 |
|
|
Capital Surplus |
63,373,795,312 |
63,373,795,312 |
|
|
Profit Surplus |
24,920,937,308 |
15,928,294,383 |
|
|
Total Equity |
89,294,732,620 |
80,302,089,695 |
|
|
Liab. & Shareholder’s Equity |
176,380,999,684 |
135,023,006,082 |
|
Income
Statement
|
|||
|
Unit : Korean Won |
As of 12/31/2011 |
As of 12/31/2010 |
As of 12/31/2009 |
|
Revenues |
132,837,744,799 |
91,698,215,718 |
|
|
Operating Expenses |
122,073,257,193 |
81,492,191,494 |
|
|
Cost of Sold Goods |
107,845,972,478 |
73,108,260,712 |
|
|
Selling
& Admin. Expenses |
14,063,799,694 |
8,247,162,457 |
|
|
R&D |
163,485,021 |
136,768,325 |
|
|
Other
Operating Income |
17,163,967 |
-165,614,329 |
|
|
Operating Income |
10,781,651,573 |
10,040,409,895 |
|
|
Finance
Income |
-733,292,857 |
32,483,204 |
|
|
Income Before Taxes |
10,048,358,716 |
10,072,893,099 |
|
|
Income Before Taxes |
1,198,354,884 |
2,565,535,779 |
|
|
Net Income |
8,850,003,832 |
7,507,357,320 |
|
Cash
Flows
|
|||
|
Unit : Korean Won |
As of 12/31/2011 |
As of 12/31/2010 |
As of 12/31/2009 |
|
Operating
Activities Cash Flows |
564,334,495 |
11,126,406,309 |
|
|
Cash Flows from Operating |
4,268,108,346 |
13,114,632,970 |
|
|
Net Income |
8,850,003,832 |
7,507,357,320 |
|
|
Adjustment |
8,691,730,498 |
5,353,179,793 |
|
|
Changes in Asset/ & Liability |
-13,273,625,984 |
254,095,857 |
|
|
Interests Received |
90,322,543 |
203,803,817 |
|
|
Interests Paid |
-711,875,754 |
-32,806,703 |
|
|
Income Taxes |
-3,082,220,640 |
-2,159,223,775 |
|
|
Cash
Flows from Investing |
-22,173,037,835 |
-34,613,815,069 |
|
|
Cash
Flows from Financing |
24,398,312,765 |
20,442,967,358 |
|
|
Increase/Decrease
in Cash |
2,789,609,425 |
-3,044,441,402 |
|
|
Cash at
the Beginning of Year |
1,191,566,962 |
4,240,597,493 |
|
|
Cash at
the End of Year |
3,981,176,387 |
1,191,566,962 |
|
|
Main Products & Services |
Ursodeoxycholic Acid, Amoxicillin, Ceftriaxone Sodium, Coenzyme Q10,
Cefodizime Sodium, Cefotiam Hydrochloride, Lansoprazole, Fluconazole |
|
Competitors |
YUHAN CORPORATION 49-6, DAEBANG-DONG, DONGJAK-GU, SEOUL,
KOREA TEL:+82-2-828-0181 FAX:+82-2-828-0300 KUNWHA PHARMACEUTICAL CO., LTD. 94, GARAKBON-DONG, SONGPA-GU, SEOUL, KOREA TEL:+82-2-2047-7700 FAX:+82-2-430-1135 YUHAN CHEMICAL INC. 5BA-402, SIHWA INDUSTRIAL COMPLEX, 678-1,
SEONGGOK-DONG, DANWON-GU, ANSAN-SI, GYEONGGI-DO, KOREA TEL:+82-31-488-5800 FAX:+82-31-499-4115 |
(Subsidiaries, Joint-Venture & Affiliates)
|
Affiliates |
DAEWOONG CO., LTD.(110111-2857146) DAEWOONG INTERNATIONAL
CORP.(110111-0742985) R&P KOREA CO., LTD.(110111-0358021) DAEWOONG MANEGEMENT DEVELOPMENT
INSTITUTE(110111-0776463) CG BIO CO., LTD. DAEWOONG PHARMACEUTICAL CO.,
LTD.(134811-0075342) DAEWOONG CHEMICAL CO., LTD.(131112-0004827) DAEWOONG NUTRITIONS CO.,
LTD.(210111-0013294) EZMEDICOM CO., LTD.(110111-2063818) SANWOONG DEVELOPMENT CO.,
LTD.(110111-0978671) SANWOONG ENGINEERING CO.,
LTD.(134811-0034421) PHARMPAC CO., LTD.(134811-0048307) PAGE1 CO., LTD.(110111-1771040) DAEWOONG DEVELOPMENT CO.,
LTD.(131111-0083649) IDS&TRUST CO., LTD.(110111-1234006) BEST SYSTEM CO., LTD.(110111-1639850) JEJU MOVIELAND CO., LTD.(224111-0014832) D&P NATURAL MATERIAL RESEARCH
INSTITUTE(134511-0102026) HEALIENCE CO., LTD.(110111-3265778) BIO AGE CO., LTD.(110111-2458689) MD WELL INC.(110111-3716854) HR GROUP CO., LTD. TRUST CO., LTD. BIO ALPHA CO., LTD.(110111-1904518) DAEWOONG PHARMACEUTICAL(THAILAND)CO., LTD DAEWOONG PHARM PHILIPPINES, INCORPORATED BEIJING DAEWOONG PHARMACEUTICAL R&D
CENTER CO., LTD. PT DAEWOONG RIASIMA INDONESIA (50.0% held by the subject company) |
|
Subsidiary |
SACHUN DAEWOONG BIO TECHNOLOGY CO., LTD.(CHINA) (66.0% held by the subject company) BIO ALPHA CO., LTD.(110111-1904518) (66.0% held by the subject company) |
|
Corporate Ownership |
DAEWOONG CO., LTD.(110111-2857146) |
|
Major Shareholders |
DAEWOONG CO., LTD.(110111-2857146) |
|
Cooperative Enterprise |
-Insured Company DONGBU INSURANCE CO., LTD.(110111-0095285) HANWHA GENERAL INSURANCE CO., LTD.(110111-0006456) LIG INSURANCE CO., LTD.(110111-0017859) |
(Activity & Markets)
The Subject deals
with the companies in China, Taiwan, India, Japan, Russia and USA.
|
Case No. |
Court |
Plaintiff(s)/
Creditor(s)/ Applicant(s) |
Defendant(s)/
Debtor(s)/ Respondent(s) |
Cause |
Amount (KRW) |
Status |
|
|
|
The Subject Company |
An Individual |
Claim for Compensation from Damages |
575,000,000 |
Proceeding |
|
|
|
The Subject Company |
ED CO., LTD.(Korea) |
Claim for Compensation from Damages |
51,324,000 |
Proceeding |
--
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.47 |
|
UK Pound |
1 |
Rs.86.60 |
|
Euro |
1 |
Rs.68.66 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.